Pita-Calandre E, Rodríguez-López C M, Cano M D, Peña-Bernal M
Instituto de Neurociencias, Universidad de Granada, España.
Rev Neurol. 1998 Nov;27(159):785-9.
It is known that anticonvulsants are able to modify lipid profile; nevertheless the initial studies were performed in patients or polytherapy whereas later investigations were carried out mostly in children.
To evaluate serum lipids, lipoproteins and apolipoproteins in adult epileptic patients on monotherapy.
Total cholesterol, triglycerides, low- and high-density lipoprotein cholesterol (including the HDL2 and the HDL3 subfractions) and apolipoproteins A1 and B were measured in 120 epileptics patients treated with carbamazepine (n = 42), sodium valproate (n = 38) and phenytoin (n = 40) and compared with the values of 48 healthy subjects.
Most of the measured parameters were significantly higher in patients receiving carbamazepine or phenytoin; carbamazepine-treated subjects showed specifically an increase in HDL2 lipoprotein cholesterol, whereas phenytoin-treated subjects showed specifically an increase of triglycerides; all of the observed alterations, save the increase in HDL lipoprotein cholesterol and apolipoprotein A1, were significant in women but not in men. Carbamazepine nor phenytoin related changes showed any correlation with the dose or the plasma levels of the drugs. No relevant modifications of serum lipids were seen in patients who received sodium valproate.
The observed alterations in serum lipids were associated to the use of anticonvulsants with enzyme inducing activity and showed significant differences between both sexes.
已知抗惊厥药能够改变血脂水平;然而,最初的研究是在接受联合治疗的患者中进行的,而后来的研究大多是在儿童中开展的。
评估接受单一疗法的成年癫痫患者的血脂、脂蛋白和载脂蛋白水平。
对120例接受卡马西平治疗(n = 42)、丙戊酸钠治疗(n = 38)和苯妥英治疗(n = 40)的癫痫患者测定总胆固醇、甘油三酯、低密度和高密度脂蛋白胆固醇(包括HDL2和HDL3亚组分)以及载脂蛋白A1和B,并与48名健康受试者的值进行比较。
接受卡马西平或苯妥英治疗的患者中,大多数测量参数显著更高;接受卡马西平治疗的受试者HDL2脂蛋白胆固醇尤其升高,而接受苯妥英治疗的受试者甘油三酯尤其升高;除HDL脂蛋白胆固醇和载脂蛋白A1升高外,所有观察到的改变在女性中显著,在男性中则不然。卡马西平和苯妥英相关的变化与药物剂量或血浆水平均无相关性。接受丙戊酸钠治疗的患者未观察到血清脂质的相关改变。
观察到的血清脂质改变与使用具有酶诱导活性的抗惊厥药有关,且在两性之间存在显著差异。